Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174590 · ClinicalTrials.gov registry record · Phase 3
Treatment of Major Depressive Disorder With Psychotic Features.
A Phase 3 study, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00174590: Clinical Trial Phase 3 study, sponsored by Rush University Medical Center.
NCT00174590 is a Phase 3 study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00174590, a Phase 3 study, was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of risperidone monotherapy in the treatment of psychotic depression. We hypothesize that risperidone is as equally as effective as haloperidol plus sertraline for depression with psychotic features
Interventions
- DRUG risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-09 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Why NCT00174590 stopped before completion
NCT00174590 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which risperidone is the first listed.
NCT00174590 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00174590 about?
NCT00174590 is a clinical study titled "Treatment of Major Depressive Disorder With Psychotic Features.". The purpose of this study is to determine the safety and efficacy of risperidone monotherapy in the treatment of psychotic depression. We hypothesize that risperidone is as equally as effective as haloperidol plus sertraline for depression with psychotic features
What is the current status of trial NCT00174590?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2001-09. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00174590?
The interventions under investigation include: risperidone (DRUG).
Who is sponsoring clinical trial NCT00174590?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00174590's enrollment target sits among peer trials
30 1917th of 2000 higher than 68 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia